$8.72
At close: Apr 16 EDT
$8.72
0.000.00%
Pre-Market: 4:12 AM EDT
Comments
Loading...
Zenas BioPharma Analyst Ratings and Price Targets | NASDAQ:ZBIO | Benzinga
Zenas BioPharma Inc has a consensus price target of $32.29 based on the ratings of 7 analysts. The high is $45 issued by Guggenheim on March 12, 2025. The low is $19 issued by Wolfe Research on February 4, 2025. The 3 most-recent analyst ratings were released by Wedbush, Guggenheim, and HC Wainwright & Co. on March 20, 2025, March 12, 2025, and March 12, 2025, respectively. With an average price target of $36.67 between Wedbush, Guggenheim, and HC Wainwright & Co., there's an implied 320.49% upside for Zenas BioPharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Guggenheim
HC Wainwright & Co.
Wolfe Research
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Zenas BioPharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 301.38% | Wedbush | Martin Fan 8% | → $35 | Initiates | → Outperform | Get Alert |
| 03/12/2025 | Buy Now | 416.06% | Guggenheim | Yatin Suneja46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 244.04% | HC Wainwright & Co. | Matthew Caufield32% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 117.89% | Wolfe Research | Andy Chen32% | → $19 | Initiates | → Outperform | Get Alert |
| 12/16/2024 | Buy Now | 244.04% | HC Wainwright & Co. | Matthew Caufield32% | → $30 | Initiates | → Buy | Get Alert |
| 12/11/2024 | Buy Now | 301.38% | Morgan Stanley | Vikram Purohit38% | $40 → $35 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | — | Guggenheim | Yatin Suneja46% | — | Reiterates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 209.63% | Citigroup | Yigal Nochomovitz54% | → $27 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 301.38% | Jefferies | Roger Song30% | → $35 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 358.72% | Morgan Stanley | Vikram Purohit38% | → $40 | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | 416.06% | Guggenheim | Yatin Suneja46% | → $45 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Zenas BioPharma (ZBIO) stock?
The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by Wedbush on March 20, 2025. The analyst firm set a price target for $35.00 expecting ZBIO to rise to within 12 months (a possible 301.38% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zenas BioPharma (ZBIO)?
The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by Wedbush, and Zenas BioPharma initiated their outperform rating.
When was the last upgrade for Zenas BioPharma (ZBIO)?
There is no last upgrade for Zenas BioPharma
When was the last downgrade for Zenas BioPharma (ZBIO)?
There is no last downgrade for Zenas BioPharma.
When is the next analyst rating going to be posted or updated for Zenas BioPharma (ZBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Zenas BioPharma (ZBIO) correct?
While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a initiated with a price target of $0.00 to $35.00. The current price Zenas BioPharma (ZBIO) is trading at is $8.72, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.